Cambridge, United Kingdom

Thomas Glanmor Davies



 

Average Co-Inventor Count = 6.2

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • Cambridgeshire, GB (2018)
  • Cambridge, GB (2013 - 2019)

Company Filing History:


Years Active: 2013-2019

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: Innovator Thomas Glanmor Davies and His Contributions to NRF2 Research

Introduction

Thomas Glanmor Davies is an accomplished inventor based in Cambridge, GB. With a total of five patents to his name, Davies has made significant contributions to the field of pharmaceutical science, particularly in the area of NRF2 regulation. His innovative work continues to influence drug development and therapeutic applications.

Latest Patents

Davies holds several notable patents, including:

1. **Biaryl Pyrazoles as NRF2 Regulators** - This invention pertains to biaryl pyrazole compounds of Formula (I), outlining methods for their synthesis, pharmaceutical compositions containing these compounds, and their utility as NRF2 regulators.

2. **Arylcyclohexyl Pyrazoles as NRF2 Regulators** - This patent focuses on arylcyclohexyl pyrazole compounds of Formula (I), detailing methods for their production, as well as their application in pharmaceutical contexts as NRF2 regulators.

Career Highlights

Throughout his career, Thomas Glanmor Davies has been associated with prominent organizations such as Astex Therapeutics Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these companies has played a pivotal role in his innovations, allowing him to apply his research in practical, impactful ways.

Collaborations

Davies is known for collaborating with talented individuals in his field. Two notable coworkers include Alison Jo-Anne Woolford and David Norton. Their combined expertise has undoubtedly contributed to the success of their projects and advancements in NRF2 research.

Conclusion

With a strong background in pharmaceutical sciences and five patents to his credit, Thomas Glanmor Davies stands out as a key innovator in NRF2 regulation. His continued efforts within the industry showcase the importance of innovation in developing effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…